Biotech News

Taysha Gene Therapies Announces Completion of Dosing in REVEAL Pivotal Trial and Reports Longer-Term Clinical Data from Part A of REVEAL Phase 1/2 Trials Evaluating TSHA-102 for Rett Syndrome

Taysha Gene Therapies (TSHA)Taysha Gene Therapies2026-06-25 13:46 ESTFDA / regulatory

Completed dosing of 17 patients in REVEAL pivotal trial; topline data from 6 ‑ month interim analysis and FDA feedback on next steps toward BLA submission pathway expected 1H 2027 TSHA-102 was generally well-tolerated with no treatment-related SAEs or DLTs reported as of the June 2026 data cutoff

Open original release

Related news

TSHATaysha Gene Therapies2026-06-25 20:01 EST

Taysha Gene Therapies Announces Multiple Presentations Highlighting its TSHA-102 Clinical Program at the 2026 IRSF Rett Syndrome Scientific Meeting

TSHATaysha Gene Therapies2026-06-25 13:46 EST

Taysha Gene Therapies Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants

TSHATaysha Gene Therapies2026-06-25 13:46 EST

Taysha Gene Therapies Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

TSHATaysha Gene Therapies2026-06-25 13:46 EST

Taysha Gene Therapies Announces Progress Across TSHA-102 Pivotal Gene Therapy Program in Rett Syndrome

TSHATaysha Gene Therapies2026-06-25 13:46 EST

Taysha Gene Therapies to Release Full-Year 2025 Financial Results and Host Conference Call and Webcast on March 19

TSHATaysha Gene Therapies2026-06-25 13:46 EST

Taysha Gene Therapies Reports Full-Year 2025 Financial Results and Provides Corporate Update

TSHATaysha Gene Therapies2026-06-25 13:46 EST

Taysha Gene Therapies Reports First Quarter 2026 Financial Results and Provides Corporate Update

TSHATaysha Gene Therapies2026-06-25 13:46 EST

Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

TSHATaysha Gene Therapies2026-06-25 13:46 EST

Taysha Gene Therapies to Release First Quarter 2026 Financial Results and Host Conference Call and Webcast on May 6

TSHATaysha Gene Therapies2026-06-25 13:46 EST

Taysha Gene Therapies to Present New Preclinical Data Supporting Construct Design of TSHA-102 for Rett Syndrome at the ASGCT 2026 Annual Meeting

View all latest news

Taysha Gene Therapies

Taysha Gene Therapies is a biopharmaceutical company focused on advancing a pipeline of therapeutic programs. Investors usually track how clinical data, regulatory milestones, and launch execution change the story over time.

Recent company news

TSHAZimmer Biomet2026-07-14 12:13 EST

Zimmer Biomet Names Chintan Desai President of Asia Pacific Region

TSHAZimmer Biomet2026-07-13 12:14 EST

Zimmer Biomet Announces Webcast and Conference Call of Second Quarter 2026 Financial Results

TSHABMYBristol-Myers Squibb Company2026-07-13 10:59 EST

U.S. Food and Drug Administration Accepts Bristol Myers Squibb's New Drug Application for Mezigdomide in Patients with Relapsed or Refractory Multiple Myeloma

TSHAGSK plc2026-07-13 07:00 EST

Jemperli (dostarlimab) achieves sustained clinical complete responses in dMMR/MSI-H locally advanced rectal cancer

TSHAMerck2026-07-10 19:01 EST

FDA Approves KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Each With Padcev® (enfortumab vedotin-ejfv), as Treatment Before and After Surgery for Adults With Muscle-Invasive Bladder Cancer (MIBC)

Stock data

Close: 5.38 USD
Market cap: 1.82B USD
Exchange: NASDAQ
Sector: Biotechnology
Location: United States